Search

Blythe G Thomson

age ~58

from Cincinnati, OH

Get Report
Also known as:
  • Blythe Scott Thomson
  • Blythe G T Sutherland
  • Blythe Thompson
  • Grace Thomson Blythe
Related to:
Connected to:

Blythe Thomson Phones & Addresses

  • Cincinnati, OH
  • Vonore, TN
  • Chestnut Hill, MA
  • 16 Fredette Rd, Newton Center, MA 02459
  • Newton, MA
  • 433 Sky Country Way NW, Issaquah, WA 98027
  • Seattle, WA
  • Loveland, OH
  • Indianapolis, IN
  • Hamilton, OH
  • Worthington, OH

Work

  • Company:
    SEATTLE CHILDRENS HOSPITAL
  • Address:
    4800 Sand Point Way Ne, Seattle, WA 98105
  • Phones:
    206 987-2000

Education

  • School / High School:
    Ohio State University / College of Medicine
    1992

Languages

English

Awards

Healthgrades Honor Roll

Ranks

  • Certificate:
    Pediatric Oncology & Pediatric Hematology, 2008

Specialities

Pediatric Hematology & Oncology

Medicine Doctors

Blythe Thomson Photo 1

Dr. Blythe Thomson, Seattle WA - MD (Doctor of Medicine)

view source
Specialties:
Pediatric Hematology & Oncology
Address:
SEATTLE CHILDRENS HOSPITAL
4800 Sand Point Way Ne, Seattle, WA 98105
206 987-2000 (Phone)

Seattle Childrens Hmtlgy/Onclgy
4800 Sand Point Way Ne Suite Mb8.50, Seattle, WA 98105
206 987-2106 (Phone)
Certifications:
Pediatric Oncology & Pediatric Hematology, 2008
Pediatrics, 2003
Awards:
Healthgrades Honor Roll
Languages:
English
Education:
Medical School
Ohio State University / College of Medicine
Graduated: 1992
Medical School
Oh State U
Graduated: 1992
Medical School
U Of Washington
Graduated: 1992
Blythe Thomson Photo 2

Blythe Thomson, Seattle WA

Work:
Seattle Children's Hospital
4800 Sand Point Way NE, Seattle, WA 98105
Name / Title
Company / Classification
Phones & Addresses
Blythe Thomson
Doctor Of Medicine
Childrens Hospital and Regional Medical Center
Medical Laboratories
4800 Sand Point Way Ne Stop 6D-1, Seattle, WA 98105
Blythe Thomson
Doctor Of Medicine
Children's Hospital And Regional Medical Center
Medical Laboratories · Specialty (except Psychiatric and Substance Abuse) Hospitals
4800 Sand Pt Way NE, Seattle, WA 98105
6901 Sand Pt Way NE, Seattle, WA 98115
206 987-2000, 206 987-2253, 206 987-1426
Blythe Grace Thomson
Blythe Thomson MD
Pediatric Oncologist · Pediatrician · Internist
4800 Sand Pt Way NE, Seattle, WA 98105
206 987-2106

Us Patents

  • Inhibiting Mutant Isocitrate Dehydrogenase 1 (Midh-1)

    view source
  • US Patent:
    20230066088, Mar 2, 2023
  • Filed:
    Mar 21, 2022
  • Appl. No.:
    17/700027
  • Inventors:
    - Watertown MA, US
    Susan Ashwell - Carlisle MA, US
    Blythe Thomson - Cincinnati OH, US
    Alan Collis - Lexington MA, US
    Jeff Davis - Hingham MA, US
    Duncan Walker - Boulder CO, US
    Wei Lu - Newton MA, US
  • International Classification:
    A61K 31/4709
    A61P 35/00
  • Abstract:
    Patients diagnosed with a cancer harboring an IDH-1 mutation can be treated by the administration of a therapeutically effective amount of a pharmaceutical composition comprising Compound 1, a selective inhibitor of 2-HG production from mIDH-1 enzymes including the R132 mutations R132C, R132H, R132L, R132G, and R132S.

  • Inhibiting Mutant Isocitrate Dehydrogenase 1 (Midh-1)

    view source
  • US Patent:
    20210244727, Aug 12, 2021
  • Filed:
    Apr 28, 2021
  • Appl. No.:
    17/243177
  • Inventors:
    - Watertown MA, US
    Blythe THOMSON - Cincinnati OH, US
    Patrick F. KELLY - Concord MA, US
    Alan COLLIS - Lexington MA, US
    Jeff DAVIS - Hingham MA, US
    Duncan WALKER - Boulder CO, US
    Wei LU - Newton MA, US
  • International Classification:
    A61K 31/4709
    A61K 31/706
    A61P 35/00
    A61P 35/02
  • Abstract:
    Patients diagnosed with a cancer harboring an IDH-1 mutation can be treated by the administration of a therapeutically effective amount of a pharmaceutical composition comprising Compound 1, a selective inhibitor of 2-HG production from mIDH-1 enzymes including the R132 mutations R132C, R132H, R132L, R132G, and R132S.

  • Treating Patients Harboring An Isocitrate Dehydrogenase 1 (Idh-1) Mutation

    view source
  • US Patent:
    20210085669, Mar 25, 2021
  • Filed:
    Dec 4, 2020
  • Appl. No.:
    17/112269
  • Inventors:
    - Watertown MA, US
    Alan Collis - Lexington MA, US
    Jeff Davis - Hingham MA, US
    Duncan Walker - Boulder CO, US
    Susan Ashwell - Carlisle MA, US
    Blythe Thomson - Cincinnati OH, US
    Wei Lu - Newton MA, US
  • International Classification:
    A61K 31/4709
    A61P 35/02
    C12Q 1/686
    C12Q 1/6886
  • Abstract:
    Methods of treating patients diagnosed with AML or MDS harboring mutant IDH-1 include detecting an IDH1 mutation and the therapeutic administration of an inhibitor of a mutant IDH-1 as a single agent, or in combination with azacitidine (AZA) or cytarabine.

  • Inhibiting Mutant Idh-1

    view source
  • US Patent:
    20200108060, Apr 9, 2020
  • Filed:
    Nov 25, 2019
  • Appl. No.:
    16/693585
  • Inventors:
    - Watertown MA, US
    Alan Collis - Lexington MA, US
    Jeff Davis - Hingham MA, US
    Duncan Walker - Boulder CO, US
    Susan Ashwell - Carlisle MA, US
    Blythe Thomson - Newton MA, US
  • International Classification:
    A61K 31/4709
    A61P 35/00
    A61K 9/00
  • Abstract:
    Methods of treating patients diagnosed with cancer harboring an IDH-1 mutation are provided, including the therapeutic administration of a certain inhibitor of a mutant IDH-1 as a single agent, or in combination with azacitidine (AZA).

  • Treatment Of Leukemia Via The Administration Of Dot1L Inhibitor Pinometostat

    view source
  • US Patent:
    20200009176, Jan 9, 2020
  • Filed:
    May 17, 2019
  • Appl. No.:
    16/415325
  • Inventors:
    - Cambridge MA, US
    Scott R. DAIGLE - Newburyport MA, US
    Eric HEDRICK - Summit NJ, US
    Nigel WATERS - Belmont MA, US
    Blythe THOMSON - Newton MA, US
  • International Classification:
    A61K 31/7076
    A61P 35/02
  • Abstract:
    The present invention relates to DOT1L inhibitors. The present invention also relates to pharmaceutical compositions containing these compounds and methods of treating disorders in which DOT1-mediated protein methylation plays a part, such as cancer, by administering these compounds and pharmaceutical compositions to subjects in need thereof

  • Inhibiting Mutant Idh-1

    view source
  • US Patent:
    20190350919, Nov 21, 2019
  • Filed:
    May 16, 2019
  • Appl. No.:
    16/414505
  • Inventors:
    - Watertown MA, US
    Alan Collis - Lexington MA, US
    Jeff Davis - Hingham MA, US
    Duncan Walker - Boulder CO, US
    Susan Ashwell - Carlisle MA, US
    Blythe Thomson - Newton MA, US
  • International Classification:
    A61K 31/4709
    A61K 9/00
    A61P 35/00
  • Abstract:
    Methods of treating patients diagnosed with cancer harboring an IDH-1 mutation are provided, including the therapeutic administration of a certain inhibitor of a mutant IDH-1 as a single agent, or in combination with azacitidine (AZA).

  • Treatment Of Leukemia Via The Administration Of Dot1L Inhibitor Pinometostat

    view source
  • US Patent:
    20190076455, Mar 14, 2019
  • Filed:
    Dec 4, 2015
  • Appl. No.:
    15/533205
  • Inventors:
    - Cambridge MA, US
    Scott R. DAIGLE - Newburyport MA, US
    Eric HEDRICK - Summit NJ, US
    Nigel WATERS - Belmont MA, US
    Blythe THOMSON - Newton MA, US
  • International Classification:
    A61K 31/7076
    A61P 35/02
  • Abstract:
    The present invention relates to a method for the treatment of leukemia and the induction of leukemic blast cell maturation or differentiation via the administration of the DOT1L inhibitor pinometostat (otherwise known as EPZ-5676; CAS Registry number 1380288-87-8) or its N-oxide or pharmaceutically acceptable salt thereof.

  • Methods For Treating Cancer

    view source
  • US Patent:
    20160296548, Oct 13, 2016
  • Filed:
    Nov 13, 2014
  • Appl. No.:
    15/036544
  • Inventors:
    - Cambridge MA, US
    Scott R. Daigle - Newburyport MA, US
    Eric Hedrick - Summit NJ, US
    Nigel Waters - Belmont MA, US
    Blythe Thomson - Newton MA, US
  • International Classification:
    A61K 31/7076
  • Abstract:
    The present invention relates to DOT1L inhibitors. The present invention also relates to pharmaceutical compositions containing these compounds and methods of treating disorders in which DOT1-mediated protein methylation plays a part, such as cancer, by administering these compounds and pharmaceutical compositions to subjects in need thereof.

Youtube

The cast of 'Anne with an E' plays Jam or Not...

The cast of 'Anne with an E' plays Jam or Not a Jam

"It's not great music, but it's really lovely to listen to..." We gave...

  • Duration:
    2m 6s

Fighting Men of Rhodesia ep98 | Sqn. Ldr. Joh...

Fighting Men of Rhodesia ep98 | Sqn. Ldr. John Bly...

Squadron Leader John Blythe-Wood, BCR, was a pilot who participated in...

  • Duration:
    40m 28s

Gene Editing Interview

Gene Editing Interview

Chair: Blythe Thomson, M.D., Senior Director, Medical Affairs, Hematol...

  • Duration:
    42m 44s

Blythe Winner

Blythe Winner

Music from Uppbeat (free for Creators!): "Can't Stop Chasing you"

  • Duration:
    4m 1s

Anne with an E Cast Names and Real Age 2019

Anne with an E Cast Names and Real Age 2019

Amybeth McNulty ... Anne Shirley-Cuthbert Geraldine James ... Marilla ...

  • Duration:
    3m 18s

Assassinating Thomson by Bruce Horak | 2021 S...

Assassinating Thomson by Bruce Horak | 2021 Season...

Performed & Created by Bruce Horak Originally Directed by Ryan Gladsto...

  • Duration:
    2m 16s
Get Report for Blythe G Thomson from Cincinnati, OH, age ~58
Control profile